Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia

被引：0
|
作者：
Fabio Gil
Fabian Juliao-Baños
Luisa Amador
Natalia Castano
Juan Manuel Reyes
机构：
[1] Clinica Colombia,
[2] Hospital Pablo Tobon Uribe,undefined
[3] Pfizer SAS,undefined
来源：
PharmacoEconomics - Open | 2022年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：837 / 846
页数：9
相关论文
共 50 条
  • [1] Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
    Gil, Fabio
    Juliao-Banos, Fabian
    Amador, Luisa
    Castano, Natalia
    Reyes, Juan Manuel
    PHARMACOECONOMICS-OPEN, 2022, 6 (06) : 837 - 846
  • [2] COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN COLOMBIA
    Hansen, Tawnya
    Mak, Joyce
    Underwood, Fox
    Windsor, Joseph
    King, James
    Quan, Joshua
    Buie, Michael
    Coward, Stephanie
    Frolkis, Alex
    Leung, Alexander
    Ma, Christopher
    Novak, Kerri
    Panaccione, Remo
    Qian, Yiming
    Burisch, Johan
    Gearry, Richard
    Ng, Siew
    Kaplan, Gilaad
    INFLAMMATORY BOWEL DISEASES, 2022, 28 : S44 - S44
  • [3] COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN COLOMBIA
    Gil, Fabio
    Julian-Banos, Fabian
    Amador, Luisa
    Castano, Natalia
    Reyes, Juan
    GASTROENTEROLOGY, 2022, 162 (03) : S44 - S44
  • [4] Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece
    Vellopoulou, Katerina
    Stefanou, Garyfallia
    Tzanetakos, Charalampos
    Boubouchairopoulou, Nantia
    Nakou, Magdalini
    Gourzoulidis, George
    Kourlaba, Georgia
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (03) : 325 - 333
  • [5] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN GREECE
    Vellopoulou, K.
    Stefanou, G.
    Tzanetakos, C.
    Boubouchairopoulou, N.
    Nakou, M.
    Kourlaba, G.
    VALUE IN HEALTH, 2019, 22 : S619 - S620
  • [6] Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience
    Parra-Izquierdo, Viviana
    Frias-Ordonez, Juan Sebastian
    Marquez, Juan Ricardo
    Juliao-Banos, Fabian
    Galindo, Pablo
    Cuadros, Carlos
    Rojas, Carlos
    Rojas, Nelson
    Ardila, Oscar
    Tovar-Fierro, German
    Garcia-Duperly, Rafael
    Vargas, Melquicedec
    Florez-Sarmiento, Cristian
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2023, 46 (07): : 512 - 521
  • [7] Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
    Danese, Silvio
    D'Amico, Ferdinando
    Bonovas, Stefanos
    Peyrin-Biroulet, Laurent
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (10) : 2106 - 2112
  • [8] COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN
    Menchen, L.
    de Andres-Nogales, F.
    Garcia, S.
    Sanchez-Guerrero, A.
    Menchen, B.
    Cabez, A.
    Gomez, S.
    Lopez, A.
    Casado, M. A.
    Peral, C.
    Taxonera, C.
    VALUE IN HEALTH, 2019, 22 : S619 - S619
  • [9] COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH INFLIXIMAB, ADALIMUMAB, GOLIMUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS IN GERMANY
    Quon, P.
    Sardesai, A.
    Milev, S.
    DiBonaventura, M.
    Cappelleri, J. C.
    Kisser, A.
    Modesto, I
    Dietz, L.
    Dignass, A.
    Bargo, D.
    VALUE IN HEALTH, 2019, 22 : S617 - S617
  • [10] Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian Real world
    Parra-Izquierdo, Viviana
    Frias-Ordonez, Juan Sebastian
    Cuadros, Carlos
    Vargas, Melquicedec
    Chamorro, Jose Fernando Vera
    Sanchez, Consuelo Romero
    Florez-Sarmiento, Cristian
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2024, 47 (06): : 574 - 581
12345